The US Food and Drug Administration (FDA) has approved AstraZeneca’s asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.
The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.
The project will use the artificial intelligence specialist’s cell-centered models and deconvolutions to gain insights for each individual asthma endotype.
The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.
England’s High Court throws out the claim that Sandoz’s inhaler product passed off the appearance of GSK’s rival through its use of the color purple in packaging.
Mylan’s recently FDA-approved Advair Diskus generic to be offered at 70% cost reduction to its reference drug, and 67% less than GSK’s generic version.
AstraZeneca has committed A$100m ($76.4m) to expand its manufacturing facility in Sydney Australia, citing growing demand for asthma medications in China.
GSK has confirmed its new UK plant will continue to supply the US with Ellipta inhalers after capacity at its facility in North Carolina comes online this year.
GlaxoSmithKline is unconcerned about losing its position in the respiratory market as Mylan launches the first generic version of blockbuster asthma product Seretide in the UK.
Shire has acquired privately-held Meritage for an upfront fee of $70m and additional contingent payments based on the achievement of development and regulatory milestones.
Lupin will co-develop a rival to GSK’s Advair in the US and has licensed rights to an inhaled drug delivery tech competitor for Forest Labs’s Aerochamber.
US FDA approval of the inhaled corticosteroid (ICS) asthma drug Arnuity will help offset declining sales of the off-patent bestseller Advair, says GlaxoSmithKline.
Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.
GlaxoSmithKline has issued upbeat guidance despite a 12% fall in sales of its blockbuster asthma and COPD drug Advair, as new products enter the respiratory drug market.
Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules to treat respiratory diseases.
Hovione has obtained a US patent for a cheap capsule-based dry powder inhaler that it claims is cheaper for manufacturers to produce and easier for patients to use.
The licensing and potential purchase of the Taper Dry Powder Inhaler (DPI) technology from 3M complements Adamis’ portfolio and future formulation expansion, Adamis says.
Dry powder inhaler firms may soon be able to eliminate lactose from formulations if a new high dispersibility particle production platform is successful in trials.
Aptar Pharma says its new eDevices can help companies gain quicker regulatory approval for their nasal drug products without having to re-do clinical trials.
in-PharmaTechnologist presents its round-up of the latest drug delivery developments, including multi-component particles, metering valve technology and crystalline salts.
Pfizer will sell Mylan its dry-powder inhaler delivery system in an agreement set to pit the generics firm against UK drug major GlaxoSmithKline (GSK).
Cambridge Consultants and Sun Pharma have developed a dry powder inhaler that administers a metered dose of the drug to the deep lung, regardless of the strength of the patient’s intake of breath.
Sandoz will buy generics firm Oriel Therapeutics, adding the US company’s FreePath delivery system and Solis multi-dose dry powder inhaler to its respiratory drug technology portfolio.
The increasing incidence of chronic and “lifestyle” related disorders will fuel demand for inhalable delivery technologies over the next five years, according to a Global Industry Analysts (GIA) report.
